Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dynavox Group ABFRA:H3Q 82 Debt-to-EBITDA is 1.60 as of Jun. 2026, which is 31% below its 10-year median of 2.32. GuruFocus rates FRA:H3Q with a GF Score™ of 82/100 and a GF Value™ of €7.97 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Dynavox Group AB ranks worse than 58.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Dynavox Group AB's Debt-to-EBITDA or its related term are showing as below:
FRA:H3Q'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.86 Med: 2.32 Max: 3.92
Current: 1.95
During the past 7 years, the highest Debt-to-EBITDA Ratio of Dynavox Group AB was 3.92. The lowest was 1.86. And the median was 2.32.
FRA:H3Q's Debt-to-EBITDA is ranked worse than 58.11% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.61
vs FRA:H3Q: 1.95
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Dynavox Group AB Debt-to-EBITDA Related Terms
Dynavox Group AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Dynavox Group AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:H3Q vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Dynavox Group AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavox Group AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Dynavox Group AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dynavox Group AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Dynavox Group AB (FRA:H3Q) has a Debt-to-EBITDA of 1.60 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dynavox Group AB. This is 31% below median its historical median of 2.32. Over the past decade, Dynavox Group AB's Debt-to-EBITDA has ranged from 1.86 to 3.92. According to the industry distribution chart, Dynavox Group AB ranks #276 out of 475 companies in the Medical Devices & Instruments industry, placing it in the top 58.1%.
Is Dynavox Group AB's Debt-to-EBITDA too high?
Dynavox Group AB's current Debt-to-EBITDA of 1.60 is 31% below median its 10-year median of 2.32. Over the past 10 years, this metric has ranged from a low of 1.86 to a high of 3.92. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.61. Dynavox Group AB's value of 1.60 is 0.6% below this industry median. Based on the distribution chart, Dynavox Group AB ranks #276 out of 475 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Dynavox Group AB has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dynavox Group AB's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Dynavox Group AB ranks #276 out of 475 companies for Debt-to-EBITDA. This places Dynavox Group AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.61. Dynavox Group AB's value of 1.60 is 0.6% below this benchmark. Historically, Dynavox Group AB's own Debt-to-EBITDA has ranged from 1.86 to 3.92 over the past decade. While the company's 10-year median is 2.32 vs. the industry median of 1.61, Dynavox Group AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.61, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dynavox Group AB's current Debt-to-EBITDA of 1.60 is 0.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Dynavox Group AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dynavox Group AB's current Debt-to-EBITDA is 1.60, which is 31% below median its own 10-year median of 2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dynavox Group AB stock overvalued right now?
Based on GuruFocus' analysis, Dynavox Group AB (FRA:H3Q) is currently considered Modestly Undervalued. The stock's GF Value™ is €7.97, compared to a current price of €6.76 — trading 15.2% below its estimated fair value. The current Debt-to-EBITDA is 1.60, which is 31% below median its 10-year median of 2.32 and 0.6% below the Medical Devices & Instruments industry median of 1.61. Dynavox Group AB's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Dynavox Group AB (FRA:H3Q), the current Debt-to-EBITDA is 1.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dynavox Group AB (FRA:H3Q) Overvalued in 2026?
Based on GuruFocus' analysis, Dynavox Group AB stock appears to be undervalued.
The current stock price of €6.76 is trading 15.2% below its estimated GF Value™ of €7.97.
GuruFocus considers Dynavox Group AB to be Modestly Undervalued.
Key valuation signals for FRA:H3Q:
Debt-to-EBITDA: 1.60 (31% below median its 10-year median of 2.32)
GF Value™: €7.97 vs. price of €6.76 (15.2% below fair value)
Industry Position: 0.6% below the Medical Devices & Instruments median (#276 of 475)
No single metric tells the full story. See the FRA:H3Q stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dynavox Group AB is engaged in assistive technology for communication. The company's Augmentative and Alternative Communication (AAC) solutions enable people with disabilities such as cerebral palsy, ALS, and spinal cord injury to communicate with a voice of their own, develop literacy skills, and live more independently. The company is a comprehensive SaaS provider with local roots. The company operates in Europe, North America, and Other countries, with the majority of revenue from North America.
82GF Score
Get the complete analysis for FRA:H3Q
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H3Q has been successfully added to your 
